ReviewBreathe (Sheffield, England)2022
How COVID-19 interacts with interstitial lung disease.
Review in Breathe (Sheffield, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- A Retrospective Observational Study of Pulmonary Impairments in Long COVID Patients.Biomedicines · 2026Article
- In reply to: "Post-COVID lung injury and the need for longitudinal histology".Croatian medical journal · 2026Article
- Place of death among adults with interstitial lung disease in the United States, 1999-2023: a national population-based study.Annals of medicine and surgery (2012) · 2026Review
- Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients.Frontiers in immunology · 2024Article
- Silico-tuberculosis amidst COVID-19 pandemic: global scenario and Indian perspective.Annals of medicine and surgery (2012) · 2023Review
- Longitudinal Analysis of Pulmonary Function Impairment One Year Post-COVID-19: A Single-Center Study.Journal of personalized medicine · 2023Article
- A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study.Journal of clinical medicine · 2023Article
- Roles of the ACE/Ang II/AT1R pathway, cytokine release, and alteration of tight junctions in COVID-19 pathogenesis.Tissue barriers · 2023Article
- Pharmacological approaches to pulmonary fibrosis following COVID-19.Frontiers in pharmacology · 2023Review
- COVID-19 Clinical Features and Outcomes in Elderly Patients during Six Pandemic Waves.Journal of clinical medicine · 2022Article
- Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort study.Respiratory research · 2022Observational
- COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy.Journal of personalized medicine · 2022Article
- Infectious disease in respiratory medicine.Breathe (Sheffield, England) · 2022Article
- Navigating the COVID-19 pandemic: Experiences and self-management approaches adopted by people with interstitial lung disease.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had far-reaching impacts on patients with interstitial lung disease (ILD), from diagnosis to management. In addition, after infection, persistent parenchymal change is associated with ongoing symptoms and functional impairment even in patients without pre-existing lung disease. The challenge of investigating and treating these patients has often fallen to ILD physicians. This review therefore seeks to explore the relationship between COVID-19 and the interstitium, as well as the model of care for patients with pre-existing ILD and those patients with persistent disease following recovery from their initial infection. Educational aims: To understand the impact of the COVID-19 pandemic on patients with existing interstitial lung disease.To explore the development of interstitial lung disease after COVID-19 infection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.